Kardigan KARD 深 沪
已收盘 10-23 16:00:00 美东时间
12.80
+0.060
+0.47%
华盛通- 最 高12.865
- 今 开12.66
- 成交量 67.98万股
- 最 低 12.335
- 昨 收 12.74
- 总市值 11.97亿
- 52周最高 27.00
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 12.23
- 委 比 -62.14%
- 总股本 9350.37万
- 历史最高 27.00
- 量 比 1.14
- 振 幅 4.16%
- 历史最低 12.23
- 每 手 1
- 风险率 3.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kardigan收涨0.47%，成交额854.32万美元
10月24日，Kardigan（KARD）收涨0.47%，报12.8美元，成交额854.32万美元，市值11.97亿美元。 行情数据 • 开盘价：12.66美元...
10-24 05:43
美股大行评级 | 潜在涨幅109.52%！富国银行上调Helus Pharma目标价至22美元，维持"超配"评级
今日重点评级关注：富国银行：维持Helus Pharma"超配"评级，目标价从16美元升至22美元；美银证券：维持SpaceX"买入"评级，目标价从235美元升至275美元
10-23 12:30
Baird Initiates Coverage On Kardigan with Outperform Rating, Announces Price Target of $43
Baird analyst Jack Allen initiates coverage on Kardigan (NASDAQ:KARD) with a Outperform rating and announces Price Target of $43.
10-22 17:29
Kardigan收跌6.12%，成交额952.68万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:42
美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
UBS Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $25
UBS analyst Alice Nettleton initiates coverage on Kardigan (NASDAQ:KARD) with a Buy rating and announces Price Target of $25.
10-12 21:48
美股大行评级 | 瑞杰金融维持英伟达"强力买入"评级，目标价从330美元升至352美元；瑞穗下调美光科技目标价从1375美元降至1300美元
今日重点评级关注：摩根大通：维持Ultragenyx Pharmaceutical"超配"评级，目标价从75美元升至80美元；瑞杰金融：维持英伟达"强力买入"评级，目标价从330美元升至352美元
08-26 08:37
JP Morgan Maintains Overweight on Kardigan, Lowers Price Target to $46
JP Morgan analyst Anupam Rama maintains Kardigan (NASDAQ:KARD) with a Overweight and lowers the price target from $51 to $46.
08-25 20:55
Kardigan Q2 EPS $(4.61) Misses $(0.71) Estimate
Kardigan (NASDAQ:KARD) reported quarterly losses of $(4.61) per share which missed the analyst consensus estimate of $(0.71) by 549.3 percent. This is a 0.65 percent increase over losses of $(4.64) per share from the same period last year.
08-11 19:55
Eye drug developer Tarsier upsizes IPO seeking nearly $50M
Tarsier Pharma (TARX), an Israel-based biopharma company focused on eye diseases, filed for an upsized initial public offering in the U.S. this week, expecting to raise nearly $50M in gross proceeds. ...
07-17 02:09
